NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.55 -0.55 (-2.28 %)
(As of 05/22/2018 03:54 PM ET)
Previous Close$24.10
Today's Range$23.50 - $24.20
52-Week Range$11.93 - $24.92
Volume11,958 shs
Average Volume856,857 shs
Market Capitalization$846.15 million
P/E Ratio-4.12
Dividend YieldN/A
Beta0.1

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Debt-to-Equity Ratio0.97
Current Ratio1.57
Quick Ratio1.48

Price-To-Earnings

Trailing P/E Ratio-4.12
Forward P/E Ratio-6.93
P/E GrowthN/A

Sales & Book Value

Annual Sales$609.95 million
Price / Sales1.33
Cash FlowN/A
Price / CashN/A
Book Value$22.34 per share
Price / Book1.05

Profitability

EPS (Most Recent Fiscal Year)($5.71)
Net Income$-199,220,000.00
Net Margins-35.17%
Return on Equity-1.15%
Return on Assets-0.47%

Miscellaneous

Employees762
Outstanding Shares34,330,000

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings data on Thursday, May, 3rd. The specialty pharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $1.10. The specialty pharmaceutical company earned $146.40 million during the quarter, compared to the consensus estimate of $149.13 million. AMAG Pharmaceuticals had a negative net margin of 35.17% and a negative return on equity of 1.15%. The business's revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for AMAG Pharmaceuticals.

What price target have analysts set for AMAG?

11 brokerages have issued 12 month price objectives for AMAG Pharmaceuticals' stock. Their predictions range from $17.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $24.2409 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "Makena autoinjector moving to launch pad. On today’s call, management commented that the autoinjector would be launched by the end of March. Pre- launch activities include the critical element of providing patient access to the drug. We believe it possible that the switch to the autoinjector could be facilitated through modulating the Makena vial (IM administration) inventory." (2/27/2018)
  • 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO & Director (Age 58)
  • Mr. Edward H. Myles MBA, Exec. VP & CFO (Age 46)
  • Mr. Joseph D. Vittiglio Esq., Exec. VP of Quality, Gen. Counsel & Sec. (Age 46)
  • Dr. Julie Krop M.D., Exec. VP & Chief Medical Officer (Age 52)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

Media coverage about AMAG stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of 0.06 on Accern's scale. They also assigned media coverage about the specialty pharmaceutical company an impact score of 46.27 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (9.73%), Dimensional Fund Advisors LP (3.33%), Northern Trust Corp (1.34%), Schwab Charles Investment Management Inc. (1.09%), Principal Financial Group Inc. (0.78%) and Principal Financial Group Inc. (0.78%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio and Julie Krop. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which major investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Palo Alto Investors LP, Schwab Charles Investment Management Inc., Highland Capital Management LP, Systematic Financial Management LP, Hikari Power Ltd, Guggenheim Capital LLC and Alambic Investment Management L.P.. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and Julie Krop. View Insider Buying and Selling for AMAG Pharmaceuticals.

Which major investors are buying AMAG Pharmaceuticals stock?

AMAG stock was bought by a variety of institutional investors in the last quarter, including Foundry Partners LLC, Hourglass Capital LLC, Piermont Capital Management Inc., ClariVest Asset Management LLC, Balter Liquid Alternatives LLC, LPL Financial LLC, Dupont Capital Management Corp and Voce Capital Management LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $23.55.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $846.15 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  283 (Vote Outperform)
Underperform Votes:  360 (Vote Underperform)
Total Votes:  643
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AMAG Pharmaceuticals (NASDAQ:AMAG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for AMAG Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.2409, suggesting that the stock has a possible upside of 2.93%. The high price target for AMAG is $45.00 and the low price target for AMAG is $17.00. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.182.182.272.14
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.2409$24.20$22.1111$24.2727
Price Target Upside: 2.93% upside20.40% upside59.07% upside73.13% upside

AMAG Pharmaceuticals (NASDAQ:AMAG) Consensus Price Target History

Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2018Leerink SwannInitiated CoverageMarket Perform$26.00 ➝ $24.65MediumView Rating Details
3/14/2018B. RileyBoost Price TargetNeutral ➝ Neutral$16.00 ➝ $23.00MediumView Rating Details
3/5/2018Jefferies GroupDowngradeBuy ➝ Hold$21.00 ➝ $20.00LowView Rating Details
3/1/2018Piper Jaffray CompaniesReiterated RatingHold$20.00MediumView Rating Details
2/28/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.00MediumView Rating Details
2/27/2018CowenReiterated RatingHold$25.00MediumView Rating Details
2/27/2018Cantor FitzgeraldReiterated RatingHold$17.00MediumView Rating Details
2/15/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$16.65 ➝ $45.00HighView Rating Details
8/31/2017Deutsche BankReiterated RatingHold$24.00LowView Rating Details
7/7/2017CitigroupLower Price TargetHold$24.00LowView Rating Details
6/1/2017BarclaysReiterated RatingEqual Weight$25.00 ➝ $20.00LowView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 ➝ $28.00N/AView Rating Details
1/31/2017JPMorgan ChaseSet Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy ➝ HoldN/AView Rating Details
1/9/2017Raymond JamesReiterated RatingMarket Perform ➝ UnderperformN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings History and Estimates Chart

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings Estimates

2018 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.80)($0.08)($0.35)
Q2 20182($0.68)($0.02)($0.35)
Q3 20182($2.13)($0.57)($1.35)
Q4 20182($2.40)($1.44)($1.92)

AMAG Pharmaceuticals (NASDAQ AMAG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.37)N/AView Earnings Details
5/3/2018Q1 2018($0.49)($1.59)$149.13 million$146.40 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.58)$0.10$158.84 million$158.30 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.04)$1.57$166.83 million$153.74 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.58)($0.40)$158.83 million$158.39 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
2/9/2015Q4 2014$0.30$0.04$53.94 million$53.25 millionViewN/AView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
7/26/2011Q2 2011($1.08)($0.92)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.09)($0.81)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.97)($1.02)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.84)($1.15)ViewN/AView Earnings Details
3/1/2010Q4 2009($1.08)($1.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($1.45)($1.29)ViewN/AView Earnings Details
7/29/2009Q2 2009($1.53)($1.55)ViewN/AView Earnings Details
4/30/2009Q1 2009($1.30)($1.55)ViewN/AView Earnings Details
2/27/2009Q4 2008($1.40)($1.28)ViewN/AView Earnings Details
11/3/2008Q3 2008($1.12)($1.39)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.62)($1.00)ViewN/AView Earnings Details
4/25/2008Q1 2008($0.60)($0.55)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.53)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AMAG Pharmaceuticals (NASDAQ:AMAG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.00%
Insider Trading History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Joseph VittiglioEVPSell770$20.80$16,016.0032,635View SEC Filing  
8/29/2017Joseph VittiglioSVPSell1,250$16.75$20,937.5033,504View SEC Filing  
7/13/2017Julie KropSVPSell4,938$20.00$98,760.0028,336View SEC Filing  
5/1/2017Julie KropSVPSell1,891$24.45$46,234.9536,777View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.4023,668View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.006,086View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00200,721View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00202,721View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.0024,834View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.0028,834View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AMAG Pharmaceuticals (NASDAQ AMAG) News Headlines

Source:
DateHeadline
Leerink Swann Begins Coverage on AMAG Pharmaceuticals (AMAG)Leerink Swann Begins Coverage on AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - May 21 at 10:34 AM
$158.58 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter$158.58 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - May 21 at 1:54 AM
-$0.22 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter-$0.22 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - May 19 at 11:11 PM
B. Riley Comments on AMAG Pharmaceuticals, Inc.s FY2018 Earnings (AMAG)B. Riley Comments on AMAG Pharmaceuticals, Inc.'s FY2018 Earnings (AMAG)
www.americanbankingnews.com - May 17 at 7:34 AM
B. Riley Weighs in on AMAG Pharmaceuticals, Inc.s FY2022 Earnings (AMAG)B. Riley Weighs in on AMAG Pharmaceuticals, Inc.'s FY2022 Earnings (AMAG)
www.americanbankingnews.com - May 16 at 8:20 AM
Palatin Technologies (PTN) CEO Carl Spana on Q3 2018 Results - Earnings Call TranscriptPalatin Technologies' (PTN) CEO Carl Spana on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 5:53 PM
AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe ...AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe ...
globenewswire.com - May 11 at 6:06 PM
AMAG Pharmaceuticals (AMAG) Presents At 43rd Annual Deutsche Bank Healthcare Conference - SlideshowAMAG Pharmaceuticals (AMAG) Presents At 43rd Annual Deutsche Bank Healthcare Conference - Slideshow
seekingalpha.com - May 10 at 6:05 PM
AMAG Pharmaceuticals (AMAG) Upgraded by BidaskClub to BuyAMAG Pharmaceuticals (AMAG) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - May 10 at 1:03 PM
AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to MenopauseAMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause
finance.yahoo.com - May 9 at 8:12 AM
AMAG Pharmaceuticals (AMAG) Rating Increased to Buy at ValuEngineAMAG Pharmaceuticals (AMAG) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 7 at 11:10 PM
AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by BrokeragesAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 7 at 1:54 PM
Edited Transcript of AMAG earnings conference call or presentation 3-May-18 12:00pm GMTEdited Transcript of AMAG earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 8:14 AM
 Analysts Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Quarterly Sales of $154.80 Million Analysts Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Quarterly Sales of $154.80 Million
www.americanbankingnews.com - May 4 at 3:04 AM
AMAG Pharmaceuticals (AMAG) Releases Quarterly  Earnings Results, Misses Estimates By $2.50 EPSAMAG Pharmaceuticals (AMAG) Releases Quarterly Earnings Results, Misses Estimates By $2.50 EPS
www.americanbankingnews.com - May 3 at 7:46 PM
AMAG Pharmaceuticals (AMAG) CEO William Heiden on Q1 2018 Results - Earnings Call TranscriptAMAG Pharmaceuticals' (AMAG) CEO William Heiden on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 5:30 PM
AMAG Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call SlidesAMAG Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 5:30 PM
AMAG Pharmaceuticals: 1Q Earnings SnapshotAMAG Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:30 PM
AMAG Pharmaceuticals EPS of -$1.59AMAG Pharmaceuticals EPS of -$1.59
seekingalpha.com - May 3 at 8:10 AM
AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial GuidanceAMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance
globenewswire.com - May 3 at 8:10 AM
AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial GuidanceAMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance
finance.yahoo.com - May 3 at 8:10 AM
Zacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of -$0.49 Per ShareZacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of -$0.49 Per Share
www.americanbankingnews.com - May 2 at 1:15 PM
Teva (TEVA) to Report Q1 Earnings: Whats in the Cards?Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - May 1 at 5:22 PM
Calculating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)Calculating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
finance.yahoo.com - April 30 at 5:18 PM
Brokers Issue Forecasts for AMAG Pharmaceuticals, Inc.s FY2020 Earnings (AMAG)Brokers Issue Forecasts for AMAG Pharmaceuticals, Inc.'s FY2020 Earnings (AMAG)
www.americanbankingnews.com - April 27 at 11:00 AM
AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ETAMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ET
finance.yahoo.com - April 26 at 8:12 AM
Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass ...Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass ...
globenewswire.com - April 25 at 8:13 AM
Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial — Discovering Underlying Factors of Influence
finance.yahoo.com - April 24 at 8:14 AM
AMAG Pharmaceuticals (AMAG) to Release Quarterly Earnings on MondayAMAG Pharmaceuticals (AMAG) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 7:14 AM
AMAG Pharmaceuticals (AMAG) Downgraded by BidaskClubAMAG Pharmaceuticals (AMAG) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
$155.89 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter$155.89 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - April 17 at 3:44 AM
AMAG Pharmaceuticals, Inc. Expected to Post FY2020 Earnings of ($1.47) Per Share (AMAG)AMAG Pharmaceuticals, Inc. Expected to Post FY2020 Earnings of ($1.47) Per Share (AMAG)
www.americanbankingnews.com - April 16 at 3:03 AM
AMAG Pharmaceuticals (AMAG) Upgraded to Sell at ValuEngineAMAG Pharmaceuticals (AMAG) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - April 16 at 12:19 AM
-$0.48 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter-$0.48 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - April 15 at 11:11 AM
Edited Transcript of AMAG presentation 8-Mar-17 3:25pm GMTEdited Transcript of AMAG presentation 8-Mar-17 3:25pm GMT
finance.yahoo.com - April 12 at 5:44 PM
AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by AnalystsAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 1:43 PM
AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClubAMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 10:30 PM
Reader Inquiry: Antares Pharma PDUFA Date In September, Is The Stock A Buy Here?Reader Inquiry: Antares Pharma PDUFA Date In September, Is The Stock A Buy Here?
seekingalpha.com - April 10 at 8:18 AM
Janney Montgomery Scott Reaffirms Hold Rating for AMAG Pharmaceuticals (AMAG)Janney Montgomery Scott Reaffirms Hold Rating for AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - April 6 at 10:54 PM
AMAG Pharmaceuticals (AMAG) Downgraded to Hold at Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:16 PM
AMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClubAMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 6 at 11:59 AM
AMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at Piper JaffrayAMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at Piper Jaffray
www.americanbankingnews.com - April 6 at 11:31 AM
AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 5 at 7:58 PM
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory AffairsCRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
globenewswire.com - April 4 at 4:19 PM
AMAG Pharmaceuticals (AMAG) Upgraded to "Hold" at Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 12:40 AM
AMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngineAMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 1:05 PM
AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 MillionAMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 Million
www.americanbankingnews.com - March 31 at 2:44 AM
AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 29 at 5:35 PM
Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.48 Earnings Per ShareZacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - March 29 at 3:14 PM
AMAG Pharmaceuticals (AMAG) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAMAG Pharmaceuticals (AMAG) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 8:19 AM

SEC Filings

AMAG Pharmaceuticals (NASDAQ:AMAG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AMAG Pharmaceuticals (NASDAQ:AMAG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AMAG Pharmaceuticals (NASDAQ AMAG) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.